Skin fibroblast cultures from patients with inherited lysosomal enzymopathies,
alpha-N-acetylgalactosaminidase (alpha-NAGA) and
alpha-galactosidase A deficiencies (Schindler and
Fabry disease, respectively), and from normal controls were used to study in situ degradation of
blood group A and B
glycosphingolipids.
Glycosphingolipids A-6-2 (GalNAc (alpha 1-->3)[Fuc alpha 1-->2]Gal(beta1-->4)GlcNAc(beta 1-->3)Gal(beta 1--> 4)Glc (beta 1-->1')Cer, IV(2)-alpha-fucosyl-IV(3)-alpha-N-acetylgalactosaminylneolactotetraosylceramide), B-6-2 (Gal(alpha 1-->3)[Fuc alpha 1--> 2] Gal (beta 1-->4)GlcNAc(beta 1-->3)Gal(beta 1-->4)Glc(beta 1-->1')Cer, IV(2)- alpha-fucosyl-IV(3)-alpha-galactosylneolactotetraosylceramide), and globoside (GalNAc(beta 1-->3)
Gal(alpha 1-->4)Gal(beta 1-->4)Glc(beta 1-->1') Cer,
globotetraosylceramide) were
tritium labeled in their
ceramide moiety and used as natural substrates. The degradation rate of
glycolipid A-6-2 was very low in fibroblasts of all the alpha-NAGA-deficient patients (less than 7% of controls), despite very heterogeneous clinical pictures, ruling out different residual
enzyme activities as an explanation for the clinical heterogeneity. Strongly elevated urinary excretion of
blood group A
glycolipids was detected in one patient with
blood group A, secretor status (five times higher than upper limit of controls), in support of the notion that
blood group A-active
glycolipids may contribute as storage compounds in
blood group A patients. When
glycolipid B-6-2 was fed to
alpha-galactosidase A-deficient cells, the degradation rate was surprisingly high (50% of controls), while that of
globotriaosylceramide was reduced to less than 15% of control average, presumably reflecting differences in the lysosomal enzymology of polar
glycolipids versus less-polar ones. Relatively high-degree degradation of substrates with alpha-D-Galactosyl moieties hints at a possible contribution of other
enzymes.